JP2008502721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008502721A5 JP2008502721A5 JP2007527522A JP2007527522A JP2008502721A5 JP 2008502721 A5 JP2008502721 A5 JP 2008502721A5 JP 2007527522 A JP2007527522 A JP 2007527522A JP 2007527522 A JP2007527522 A JP 2007527522A JP 2008502721 A5 JP2008502721 A5 JP 2008502721A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- alkyl
- compound according
- substituents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 carboxyl ester Chemical class 0.000 claims 43
- 150000001875 compounds Chemical class 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims 2
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 2
- 235000008191 folinic acid Nutrition 0.000 claims 2
- 239000011672 folinic acid Substances 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 210000000244 kidney pelvis Anatomy 0.000 claims 2
- 229960001691 leucovorin Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 229950006410 tezacitabine Drugs 0.000 claims 2
- GFFXZLZWLOBBLO-ASKVSEFXSA-N tezacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(=C/F)/[C@H](O)[C@@H](CO)O1 GFFXZLZWLOBBLO-ASKVSEFXSA-N 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 claims 1
- 125000006334 2,4-difluoro benzoyl group Chemical group [H]C1=C([H])C(C(*)=O)=C(F)C([H])=C1F 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000003541 2-chlorobenzoyl group Chemical group ClC1=C(C(=O)*)C=CC=C1 0.000 claims 1
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 claims 1
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 claims 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims 1
- 125000006291 3-hydroxybenzyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(=C1[H])C([H])([H])* 0.000 claims 1
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 claims 1
- 125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 claims 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- RSDOASZYYCOXIB-UHFFFAOYSA-N beta-alaninamide Chemical compound NCCC(N)=O RSDOASZYYCOXIB-UHFFFAOYSA-N 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- UYTKFWJKADWKBQ-UHFFFAOYSA-N n-(3-aminopropyl)-n-[1-(3-benzyl-7-chloroquinolin-2-yl)-2-methylpropyl]-3-fluoro-4-methylbenzamide Chemical compound N=1C2=CC(Cl)=CC=C2C=C(CC=2C=CC=CC=2)C=1C(C(C)C)N(CCCN)C(=O)C1=CC=C(C)C(F)=C1 UYTKFWJKADWKBQ-UHFFFAOYSA-N 0.000 claims 1
- TVEXKRMIKGLDGZ-UHFFFAOYSA-N n-(3-aminopropyl)-n-[1-(3-benzyl-7-chloroquinolin-2-yl)-2-methylpropyl]-4-methylbenzamide Chemical compound N=1C2=CC(Cl)=CC=C2C=C(CC=2C=CC=CC=2)C=1C(C(C)C)N(CCCN)C(=O)C1=CC=C(C)C=C1 TVEXKRMIKGLDGZ-UHFFFAOYSA-N 0.000 claims 1
- VUWDJNTXMFZAOD-UHFFFAOYSA-N n-(3-aminopropyl)-n-[1-(3-benzylquinolin-2-yl)-2-methylpropyl]-3,4-dimethylbenzamide Chemical compound N=1C2=CC=CC=C2C=C(CC=2C=CC=CC=2)C=1C(C(C)C)N(CCCN)C(=O)C1=CC=C(C)C(C)=C1 VUWDJNTXMFZAOD-UHFFFAOYSA-N 0.000 claims 1
- DQOAEPATSHONEH-UHFFFAOYSA-N n-(3-aminopropyl)-n-[1-(3-benzylquinolin-2-yl)-2-methylpropyl]-3-fluoro-4-methylbenzamide Chemical compound N=1C2=CC=CC=C2C=C(CC=2C=CC=CC=2)C=1C(C(C)C)N(CCCN)C(=O)C1=CC=C(C)C(F)=C1 DQOAEPATSHONEH-UHFFFAOYSA-N 0.000 claims 1
- KYRXWHYMQRFSMR-UHFFFAOYSA-N n-(3-aminopropyl)-n-[1-(3-benzylquinolin-2-yl)-2-methylpropyl]-4-methylbenzamide Chemical compound N=1C2=CC=CC=C2C=C(CC=2C=CC=CC=2)C=1C(C(C)C)N(CCCN)C(=O)C1=CC=C(C)C=C1 KYRXWHYMQRFSMR-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57312004P | 2004-05-21 | 2004-05-21 | |
| PCT/US2005/017961 WO2005113507A1 (en) | 2004-05-21 | 2005-05-19 | Substituted quinoline derivatives as mitotic kinesin inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008502721A JP2008502721A (ja) | 2008-01-31 |
| JP2008502721A5 true JP2008502721A5 (https=) | 2008-06-19 |
Family
ID=34970815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527522A Pending JP2008502721A (ja) | 2004-05-21 | 2005-05-19 | 分裂キネシンインヒビターとしての置換キノリン誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7452996B2 (https=) |
| EP (1) | EP1753723B1 (https=) |
| JP (1) | JP2008502721A (https=) |
| CN (1) | CN1956960A (https=) |
| AT (1) | ATE404536T1 (https=) |
| AU (1) | AU2005245492A1 (https=) |
| BR (1) | BRPI0511433A (https=) |
| CA (1) | CA2564215A1 (https=) |
| DE (1) | DE602005008953D1 (https=) |
| DK (1) | DK1753723T3 (https=) |
| ES (1) | ES2311992T3 (https=) |
| HR (1) | HRP20080493T3 (https=) |
| MX (1) | MXPA06011958A (https=) |
| PL (1) | PL1753723T3 (https=) |
| PT (1) | PT1753723E (https=) |
| RS (1) | RS50670B (https=) |
| RU (1) | RU2385867C2 (https=) |
| SI (1) | SI1753723T1 (https=) |
| WO (1) | WO2005113507A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2311992T3 (es) * | 2004-05-21 | 2009-02-16 | Novartis Vaccines And Diagnostics, Inc. | Derivados de quinolina sustituida com,o inhibidores de cinesina mitotica. |
| EP1781674A1 (en) | 2004-08-18 | 2007-05-09 | AstraZeneca AB | Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US8202837B2 (en) * | 2005-11-04 | 2012-06-19 | Glaxosmithkline Llc | Methods for administering hypoglycemic agents |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| EP2091926B1 (en) * | 2006-11-13 | 2015-10-21 | Novartis AG | Substituted pyrazole and triazole compounds as ksp inhibitors |
| WO2008086122A2 (en) * | 2007-01-05 | 2008-07-17 | Novartis Ag | Imidazole derivatives as kinesin spindle protein inhibitors (eg-5) |
| FR2940289B1 (fr) * | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| MY162940A (en) | 2009-08-19 | 2017-07-31 | Eisai R&D Man Co Ltd | Quinoline derivative-containing pharmaceutical composition |
| EA201201404A1 (ru) * | 2010-04-15 | 2013-04-30 | Новартис Аг | Триазолы как ингибиторы кбв (кинезин-белок веретена) |
| WO2011128388A2 (en) * | 2010-04-15 | 2011-10-20 | Novartis Ag | Oxazole and thiazole compounds as ksp inhibitors |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| RU2486175C2 (ru) * | 2011-09-12 | 2013-06-27 | Закрытое Акционерное Общество "Фарм-Синтез" | Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений |
| US9458161B1 (en) | 2011-11-03 | 2016-10-04 | Vanderblit University | TSPO ligands for cancer imaging and treatment |
| EP2882436A1 (en) * | 2012-08-13 | 2015-06-17 | Array Biopharma, Inc. | Arry-520 for use in treating cancer in a patient with low aag |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| WO2017030146A1 (ja) * | 2015-08-19 | 2017-02-23 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 胆道癌治療剤 |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| RU2019134940A (ru) | 2017-05-16 | 2021-06-16 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Лечение гепатоцеллюлярной карциномы |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172087B1 (en) * | 1998-06-03 | 2001-01-09 | Gpi Nil Holding, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
| CA2369549A1 (en) | 1999-04-02 | 2000-10-12 | Robert W. Desimone | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics |
| US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| CZ20021428A3 (cs) | 1999-10-27 | 2002-11-13 | Cytokinetics, Inc. | Způsoby a kompozice vyuľívající chinazoliny |
| MXPA03003039A (es) | 2000-10-06 | 2003-10-15 | Neurogen Corp | Derivados de indola y bencimidazola como moduladores del receptor crf. |
| NZ526622A (en) | 2000-12-11 | 2006-07-28 | Amgen Sf Llc | CXCR3 antagonists |
| WO2002057244A1 (en) | 2001-01-19 | 2002-07-25 | Cytokinetics, Inc. | Phenothiazine kinesin inhibitors |
| EP1351671A1 (en) | 2001-01-19 | 2003-10-15 | Cytokinetics, Inc. | Triphenylmethane kinesin inhibitors |
| JP2005511581A (ja) | 2001-11-07 | 2005-04-28 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
| WO2003043995A1 (en) | 2001-11-20 | 2003-05-30 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
| US20050107404A1 (en) | 2001-12-06 | 2005-05-19 | Fraley Mark E. | Mitotic kinesin inhibitors |
| CA2468156A1 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Azolopyrimidinone compounds and their use |
| WO2003049527A2 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| JP2005515208A (ja) | 2001-12-06 | 2005-05-26 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂性キネシン阻害剤 |
| CA2467722A1 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Thienopyrimidinone derivatives as mitotic kinesin inhibitors |
| WO2003059289A2 (en) | 2002-01-10 | 2003-07-24 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
| JP2005529076A (ja) | 2002-02-15 | 2005-09-29 | サイトキネティクス・インコーポレーテッド | キナゾリノンの合成 |
| AU2003249597B2 (en) | 2002-03-08 | 2007-06-28 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| NZ536190A (en) * | 2002-04-17 | 2007-08-31 | Cytokinetics Inc | Compounds for treating cellular proliferative diseases by modulating the activity of the mitotic kinesin KSP |
| RU2004135554A (ru) | 2002-05-09 | 2006-01-20 | Цитокинетикс, Инк. (Us) | Пиримидиноны, композиции на их основе и способы их использования |
| EP1553931A4 (en) | 2002-05-09 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| EP1509507A4 (en) | 2002-05-23 | 2006-09-13 | Merck & Co Inc | INHIBITORS OF MITOTIC KINESINE |
| EP1513820A4 (en) | 2002-05-23 | 2006-09-13 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| EP1515724B1 (en) | 2002-06-14 | 2009-10-21 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| CA2489367A1 (en) * | 2002-06-14 | 2003-12-24 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| ATE356804T1 (de) | 2002-06-14 | 2007-04-15 | Merck & Co Inc | Inhibitoren von mitotischem kinesin |
| AU2003247891A1 (en) | 2002-07-08 | 2004-01-23 | Merck & Co., Inc. | Mitotic kinesin binding site |
| DE60326248D1 (de) | 2002-07-17 | 2009-04-02 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen |
| EP1537089A4 (en) | 2002-07-23 | 2008-04-16 | Cytokinetics Inc | CONNECTIONS, COMPOSITIONS AND PROCEDURES |
| WO2004018058A2 (en) | 2002-08-21 | 2004-03-04 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| EP1554265A4 (en) | 2002-09-13 | 2008-05-07 | Cytokinetics Inc | COMPOSITIONS, COMPOSITIONS AND M THODES |
| ES2311992T3 (es) * | 2004-05-21 | 2009-02-16 | Novartis Vaccines And Diagnostics, Inc. | Derivados de quinolina sustituida com,o inhibidores de cinesina mitotica. |
-
2005
- 2005-05-19 ES ES05752901T patent/ES2311992T3/es not_active Expired - Lifetime
- 2005-05-19 PT PT05752901T patent/PT1753723E/pt unknown
- 2005-05-19 DE DE602005008953T patent/DE602005008953D1/de not_active Expired - Lifetime
- 2005-05-19 SI SI200530384T patent/SI1753723T1/sl unknown
- 2005-05-19 DK DK05752901T patent/DK1753723T3/da active
- 2005-05-19 HR HR20080493T patent/HRP20080493T3/xx unknown
- 2005-05-19 AT AT05752901T patent/ATE404536T1/de not_active IP Right Cessation
- 2005-05-19 CN CNA2005800164405A patent/CN1956960A/zh active Pending
- 2005-05-19 EP EP05752901A patent/EP1753723B1/en not_active Expired - Lifetime
- 2005-05-19 RU RU2006145336/04A patent/RU2385867C2/ru not_active IP Right Cessation
- 2005-05-19 BR BRPI0511433-0A patent/BRPI0511433A/pt not_active IP Right Cessation
- 2005-05-19 US US11/133,509 patent/US7452996B2/en not_active Expired - Fee Related
- 2005-05-19 CA CA002564215A patent/CA2564215A1/en not_active Abandoned
- 2005-05-19 PL PL05752901T patent/PL1753723T3/pl unknown
- 2005-05-19 RS RSP-2008/0534A patent/RS50670B/sr unknown
- 2005-05-19 WO PCT/US2005/017961 patent/WO2005113507A1/en not_active Ceased
- 2005-05-19 AU AU2005245492A patent/AU2005245492A1/en not_active Abandoned
- 2005-05-19 MX MXPA06011958A patent/MXPA06011958A/es active IP Right Grant
- 2005-05-19 JP JP2007527522A patent/JP2008502721A/ja active Pending
-
2008
- 2008-09-30 US US12/242,360 patent/US20090028858A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008502721A5 (https=) | ||
| JP2008517057A5 (https=) | ||
| RU2006145336A (ru) | Замещенные производные хинолина, как ингибиторы митотического кинезина | |
| JP2011057693A5 (https=) | ||
| JP2008528468A5 (https=) | ||
| JP2010533205A5 (https=) | ||
| JPWO2023190748A5 (https=) | ||
| Blagosklonny | Selective anti-cancer agents as anti-aging drugs | |
| JP2006523216A5 (https=) | ||
| CA2566544A1 (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
| CA2552050A1 (en) | Substituted heterocycles and the uses thereof | |
| JP2007518822A5 (https=) | ||
| CA2493225A1 (en) | Quinoline derivatives and their use as mycobacterial inhibitors | |
| JP2017519781A5 (https=) | ||
| JP2017528487A5 (https=) | ||
| JP2005534623A5 (https=) | ||
| JP2009536191A5 (https=) | ||
| JP2011507896A5 (https=) | ||
| JP2011517697A5 (https=) | ||
| JPWO2013100014A1 (ja) | 抗腫瘍剤の効果増強剤 | |
| JP2008500999A5 (https=) | ||
| JP2005506982A5 (https=) | ||
| JP2008514718A5 (https=) | ||
| JP2012522841A5 (https=) | ||
| JP2015528814A5 (https=) |